相关实验视频
Updated: Jan 13, 2026

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.4K
一个叙述的回顾Tirzepatide在血糖控制和心脏保护中的治疗潜力
Mrudula Thiriveedi1, Francis Sto Domingo2, Hannah Yates2
1Department of Internal Medicine, Decatur Morgan Hospital, Decatur, Alabama, USA.
Annals of medicine and surgery (2012)
|January 7, 2026
概括
提尔泽帕提德是一种新型的双GLP-1/GIP激动剂,在2型糖尿病和肥胖症中显著降低HbA1c和体重. 它还可以改善心血管风险因素,并对心力衰竭和睡眠呼吸暂停有前途.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 代谢疾病 代谢疾病
- 心血管医学 心血管医学
背景情况:
- 蒂尔泽帕提德是一种新型的双GIP和GLP-1受体激动剂.
- 它代表了一类新的基于隐形素的疗法.
- 它针对的是2型糖尿病 (T2DM),肥胖和相关的并发症.
研究的目的:
- 来自关键临床试验 (SURPASS,SURMOUNT,SUMMIT) 的提尔泽帕提德疗效和安全性的综合证据.
- 评估蒂尔泽帕提德对血糖控制,体重,心血管风险因素以及HFpEF和OSA等特定疾病的影响.
主要方法:
- 对来自SURPASS,SURMOUNT和SUMMIT临床试验计划的数据进行叙述性审查.
- 对提泽帕提德对HbA1c,体重,血压,脂质,炎症,AHI和住院率的影响的分析.
主要成果:
- 蒂尔泽帕提德可以使HbA1c降低高达2.5%,体重减轻超过20%.
- 在心血管风险因素,HFpEF参数 (降低AHI) 和OSA中观察到显著改善.
- 安全性概况与GLP-1RA相似,有明显的胃肠道副作用和需要监测的胆囊事件.
结论:
- 蒂尔泽帕提德在治疗T2DM和肥胖症方面表现出显著的疗效,对心血管健康和相关疾病有额外的益处.
- 持续的试验和现实世界的数据对于理解长期结果和指导方针的整合至关重要.
- 监测特定的副作用,解决非标签使用和获取等伦理问题,对于其临床应用至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
